FB-102 is under clinical development by Forte Biosciences and currently in Phase I for Alopecia Areata. According to GlobalData, Phase I drugs for Alopecia Areata have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FB-102 overview

FB-102 is under development for the treatment of alopecia areata, graft versus host disease (GVHD), vitiligo. It acts by targeting CD122. It is administered through intravenous and subcutaneous route.
It was under development for the treatment of celiac disease.

Forte Biosciences overview

Forte Biosciences is a biopharmaceutical company that develops and commercializes product candidates for the treatment of skin. The company offers lead product candidate such as FB-102. FB-102 is used for the for the treatment of autoimmune diseases such as Vitiligo and Alopecia Areata (AA). Alopecia Areata nonscarring hair loss generally on the scalp but can also other areas of the body. Vitiligo is an autoimmune disease in which the immune system attack melanocytes?. Its services include clinical trials. The company has operations across the US. Forte Biosciences is headquartered in Torrance, California, the US.

For a complete picture of FB-102’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.